Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 12, 2018

View Archived Issues

Novartis enrolling participants in phase II trial of NIR-178

BI-2545 shows promise for the unmet medical need in IPF treatment

UCB studies bimekizumab in phase III for moderate to severe chronic plaque psoriasis

Chiesi initiates phase I/II study of CHF-6366 for asthma and COPD

Libella Gene Therapeutics begins clinical trial of telomerase gene therapy for Alzheimer's

Immunomedics enters agreement to test sacituzumab govitecan in prostate cancer

CEO describes development activity at Alkermes

Anti-MERS human antibody derived from transchromosomic cattle safe in phase I trial

Forty Seven enters two agreements for studies of Hu5F9-G4

FDA advisory committee does not recommend approval of Linhaliq

FDA advisory committee votes against testosterone replacement therapy Tlando

Novel HSPG-mimicking nanoparticles show broad-spectrum virucidal activity

HedgePath to receive new investment from Mayne Pharma

Ligand and Glenmark enter OmniAb license agreement

Aviragen reiterates support for pending merger with Vaxart

Astellas submits application for additional indication for ipragliflozin in Japan

Nippon Chemiphar's NC-2800 selected for AMED progrram

Aequus and CannaRoyalty to jointly develop cannabis-based therapies

FDA approves expanded use of Fluarix Quadrivalent from 6 months of age

FronThera US Pharmaceuticals presents novel hemoglobin modifier compounds

Syndax Pharmaceuticals, Genentech to test entinostat with atezolizumab

Bristol-Myers Squibb patents lysophosphatidic acid receptor antagonists

New nuclear receptor ROR-gamma antagonists discovered at Fudan University

Medchem Partners discovers novel nitric oxide donors

Novel HIV maturation inhibitors identified at ViiV Healthcare

Pharmazz eyes studies of PMZ-1620 in ALS

European Commission approves Ocrevus for relapsing MS and primary progressive MS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...